Literature DB >> 1659339

Inhibition of macrophage-activating cytokines is beneficial in the acute septic response.

H P Redmond1, K D Chavin, J S Bromberg, J M Daly.   

Abstract

Interferon-gamma and other cytokines enhance macrophage (M phi) antimicrobial function and have been considered for therapeutic use in sepsis. Systemic sequelae of macrophage activation, however, are unclear. This study examined the effects of M phi activating cytokines (interferon-gamma [IFN-gamma] and interleukin-4 [IL-4]) and monoclonal antibodies directed against these cytokines in modulating the acute septic response. CFW/Swiss Webster mice (n = 345) received endotoxin (lipopolysaccharide [LPS]: 60 mg/kg body weight intraperitoneally) and were randomized to five treatment groups: IFN-gamma (10(4) units), IL-4 (10(4) units), IgG1 isotype antibody (TRFK5: 200 micrograms), anti-IFN-gamma (200 micrograms), or anti-IL-4 (200 micrograms) monoclonal antibodies (MAbs) given simultaneously or 2 hours after LPS. Animals were divided into two groups and studied for mortality or measurement of peritoneal M phi superoxide anion release (O2-), tumor necrosis factor (TNF), and IL-6 production 6 hours after administration of LPS +/- experimental regimens. Serum TNF and IL-6 also were assessed at 2 and 4 hours after LPS, respectively. Administration of LPS resulted in a 27% survival compared with 10% in the IFN-gamma and 13% in the IL-4 groups. Treatment with anti-IFN-gamma offered protection against LPS lethality (93%-100% survival, p less than 0.001 vs. other groups) when given either simultaneously or 2 hours after LPS. Anti-IFN-gamma also significantly decreased PM phi O-2 and TNF release. Thus anti-IFN-gamma may have an important role in the modulation of the acute septic response.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1659339      PMCID: PMC1358556          DOI: 10.1097/00000658-199110000-00014

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  33 in total

1.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Authors:  K J Tracey; Y Fong; D G Hesse; K R Manogue; A T Lee; G C Kuo; S F Lowry; A Cerami
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

2.  Shock and tissue injury induced by recombinant human cachectin.

Authors:  K J Tracey; B Beutler; S F Lowry; J Merryweather; S Wolpe; I W Milsark; R J Hariri; T J Fahey; A Zentella; J D Albert
Journal:  Science       Date:  1986-10-24       Impact factor: 47.728

3.  Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura.

Authors:  E Girardin; G E Grau; J M Dayer; P Roux-Lombard; P H Lambert
Journal:  N Engl J Med       Date:  1988-08-18       Impact factor: 91.245

4.  Modulation of infection by gamma interferon treatment following trauma.

Authors:  M J Hershman; H C Polk; J D Pietsch; R E Shields; S R Wellhausen; G Sonnenfeld
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

5.  Interferon-gamma restores immune competence after hemorrhagic shock.

Authors:  D H Livingston; M A Malangoni
Journal:  J Surg Res       Date:  1988-07       Impact factor: 2.192

6.  Induction of class I and class II MHC antigen expression on murine bone marrow-derived macrophages by IL-4 (B cell stimulatory factor 1).

Authors:  P M Stuart; A Zlotnik; J G Woodward
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422

7.  Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.

Authors:  S Okusawa; J A Gelfand; T Ikejima; R J Connolly; C A Dinarello
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

8.  The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome.

Authors:  A Waage; P Brandtzaeg; A Halstensen; P Kierulf; T Espevik
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

9.  Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice.

Authors:  A Waage; T Espevik
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

10.  Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock.

Authors:  C Natanson; P W Eichenholz; R L Danner; P Q Eichacker; W D Hoffman; G C Kuo; S M Banks; T J MacVittie; J E Parrillo
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more
  8 in total

1.  Cholesterol regulation of receptor-interacting protein 140 via microRNA-33 in inflammatory cytokine production.

Authors:  Ping-Chih Ho; Kun-Che Chang; Ya-Shan Chuang; Li-Na Wei
Journal:  FASEB J       Date:  2011-02-01       Impact factor: 5.191

2.  Gamma interferon augments macrophage activation by lipopolysaccharide by two distinct mechanisms, at the signal transduction level and via an autocrine mechanism involving tumor necrosis factor alpha and interleukin-1.

Authors:  T K Held; X Weihua; L Yuan; D V Kalvakolanu; A S Cross
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

3.  Exogenous growth hormone: effects on the catabolic response to surgically produced acute stress and on postoperative immune function.

Authors:  R Vara-Thorbeck; J A Guerrero; J Rosell; E Ruiz-Requena; J M Capitán
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

4.  Role of gamma interferon in a neonatal mouse model of group B streptococcal disease.

Authors:  V Cusumano; G Mancuso; F Genovese; D Delfino; C Beninati; E Losi; G Teti
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

5.  Dose-dependent activation of lymphocytes in endotoxin-induced airway inflammation.

Authors:  R Larsson; D Rocksén; B Lilliehöök; A Jonsson; A Bucht
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

Review 6.  Modulating LPS signal transduction at the LPS receptor complex with synthetic Lipid A analogues.

Authors:  Aileen F B White; Alexei V Demchenko
Journal:  Adv Carbohydr Chem Biochem       Date:  2014       Impact factor: 12.200

Review 7.  The bioartificial kidney in the treatment of acute kidney injury.

Authors:  Joon Ho Song; H David Humes
Journal:  Curr Drug Targets       Date:  2009-12       Impact factor: 3.465

8.  In vivo cytokine production and recombinant interleukin 2 immunotherapy: an insight into the possible mechanisms underlying clinical responses.

Authors:  D J Deehan; S D Heys; W G Simpson; J Broom; C Franks; O Eremin
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.